Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Rachel Rodriguez, ...

McKesson Corporation. ( NYSE: MCK) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target upped by stock analysts at Guggenheim from $212.00 to $214.00 in a ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie (NYSE:ABBV – Get Free Report) had its price objective lifted by equities research analysts at BMO Capital Markets from ...

State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...

ProShares UltraPro Short QQQ, EnLink Midstream, AbbVie, Ford Motor, Exxon Mobil, United Parcel Service, and Comcast are the seven Dividend stocks to watch today, according to MarketBeat’s stock ...

Groesbeck Investment Management Corp NJ lifted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 168.6% during the 4th quarter, according to its most recent disclosure with the Securities & ...